PCV13 in the USA: Early successes and potential challenges

Chris Stockmann; Carrie L. Byington

doi:10.1016/S1473-3099(15)70018-6

PCV13 in the USA: Early successes and potential challenges

Chris Stockmann, Carrie L. Byington

Academic Institute

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	254-256
Number of pages	3
Journal	The Lancet Infectious Diseases
Volume	15
Issue number	3
DOIs	https://doi.org/10.1016/S1473-3099(15)70018-6
State	Published - Mar 1 2015

ASJC Scopus subject areas

Infectious Diseases

Access to Document

10.1016/S1473-3099(15)70018-6

Cite this

@article{1c1db2d50d384693b0941ac9d0dd19c6,

title = "PCV13 in the USA: Early successes and potential challenges",

author = "Chris Stockmann and Byington, {Carrie L.}",

note = "Funding Information: CS is supported by the American Foundation for Pharmaceutical Education's Clinical Pharmaceutical Sciences Fellowship. CLB has intellectual property in and receives royalties from BioFire Diagnostics. CLB is supported through the HA and Edna Benning Presidential Endowment, the National Center for Advancing Translational Sciences of the National Institutes of Health ( 1ULTR001067 ), and the Utah Department of Health and the United States Centers for Disease Control and Prevention ( 5U50CI00866 ).",

year = "2015",

month = mar,

day = "1",

doi = "10.1016/S1473-3099(15)70018-6",

language = "English (US)",

volume = "15",

pages = "254--256",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier Ltd",

number = "3",

}

TY - JOUR

T1 - PCV13 in the USA

T2 - Early successes and potential challenges

AU - Stockmann, Chris

AU - Byington, Carrie L.

N1 - Funding Information: CS is supported by the American Foundation for Pharmaceutical Education's Clinical Pharmaceutical Sciences Fellowship. CLB has intellectual property in and receives royalties from BioFire Diagnostics. CLB is supported through the HA and Edna Benning Presidential Endowment, the National Center for Advancing Translational Sciences of the National Institutes of Health ( 1ULTR001067 ), and the Utah Department of Health and the United States Centers for Disease Control and Prevention ( 5U50CI00866 ).

PY - 2015/3/1

Y1 - 2015/3/1

UR - http://www.scopus.com/inward/record.url?scp=84923284734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923284734&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(15)70018-6

DO - 10.1016/S1473-3099(15)70018-6

M3 - Comment/debate

C2 - 25656599

AN - SCOPUS:84923284734

SN - 1473-3099

VL - 15

SP - 254

EP - 256

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 3

ER -

PCV13 in the USA: Early successes and potential challenges

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this